The content on this site is intended for healthcare professionals only
Heat shock protein (Hsp) 90 is a ubiquitous protein that helps other proteins to fold and stabilises a number of proteins involved in tumour growth.
Dr Banjerji talks to ecancertv at TAT 2015 about his experience with Hsp90 inhibitors and the practicalities of using these drugs in the clinic.
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
